title: Role of Allogeneic Stem Cell Transplant in the Treatment of Primary Myelofibrosis.
abstract: The only known curative therapy for primary myelofibrosis is allogeneic hematopoietic stem cell transplant.
  
  
  
  We retrospectively evaluated 11 transplant procedures involving 10 patients (5 men and 5 women) diagnosed with primary myelofibrosis between 2005 and 2014.
  
  
  
  The median age at the time of transplant was 60.5 years (range, 22-62 years). Stem cell sources were unrelated (n=1) and related (n=11) peripheral blood stem cells. Conditioning regimen was myeloablative for 8 and reduced intensity for 3 transplants. The median number of infused CD34+ cells was 6.8 × 106 cells/kg (range, 3.2-10.4 × 106 cells/kg). Neutrophil and platelet engraftment occurred at median of 22 days (range, 12-31 days) and 19.5 days (range, 13-56 days). Acute and chronic graft-versus-host disease was seen in 4 of 11 allografts. Relapse and nonrelapse mortality rates were 20%. Six patients (60%) were still alive without disease after median follow-up of 68.5 months (range, 17-120 months). Median progression-free survival and overall survival were 61 months (range, 2-120 months) and 65 months (range, 2-120 months).
  
  
  
  Our results suggest that allogeneic hematopoietic stem cell transplant may provide a curative treatment for primary myelofibrosis patients. A myeloablative regimen seems to be effective and safe, especially for younger primary myelofibrosis patients.
authors.affiliation: Department of Hematology, Ege University Medical Faculty, Izmir, Turkey
authors.forename: Nur
authors.initials: N
authors.lastname: Soyer
authors.affiliation: Department of Internal Medicine, Ege University Medical Faculty, Izmir, Turkey
authors.forename: Ferit
authors.initials: F
authors.lastname: Celik
authors.affiliation: Department of Hematology, Ege University Medical Faculty, Izmir, Turkey
authors.forename: Murat
authors.initials: M
authors.lastname: Tombuloglu
authors.affiliation: Department of Hematology, Ege University Medical Faculty, Izmir, Turkey
authors.forename: Fahri
authors.initials: F
authors.lastname: Sahin
authors.affiliation: Department of Hematology, Ege University Medical Faculty, Izmir, Turkey
authors.forename: Guray
authors.initials: G
authors.lastname: Saydam
authors.affiliation: Department of Hematology, Ege University Medical Faculty, Izmir, Turkey
authors.forename: Filiz
authors.initials: F
authors.lastname: Vural
mesh_terms: D000208:Acute Disease; D000328:Adult; D000078422:Allogeneic Cells / Q000276:immunology; D018952:Antigens, CD34 / Q000276:immunology; D002908:Chronic Disease; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000008:administration & dosage; D055728:Primary Myelofibrosis / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D000077982:Progression-Free Survival; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018952:Antigens, CD34; D019653:Myeloablative Agonists